TipRanks
Europlasma SA (FR:ALEUP)
:ALEUP
Want to see FR:ALEUP full AI Analyst Report?

Europlasma SA (ALEUP) AI Stock Analysis

13 Followers

Top Page

FR:ALEUP

Europlasma SA

(ALEUP)

Select Model
Select Model
Select Model
Rating:43Neutral
Price Target:
€1.00
▲(400.00% Upside)
Action:Reiterated
Date:10/24/25
The overall score of 43 for Europlasma SA is primarily driven by weak financial performance, with significant profitability and solvency concerns despite strong revenue growth. Technical indicators further weigh on the score with bearish momentum and oversold conditions. Valuation remains neutral due to negative earnings and lack of dividend yield.
Positive Factors
Revenue Growth
Strong revenue growth indicates increasing demand for Europlasma's technology, suggesting a solid market position and potential for future expansion.
Negative Factors
Profitability Challenges
Persistent profitability issues due to high costs suggest operational inefficiencies, which could hinder long-term financial stability and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates increasing demand for Europlasma's technology, suggesting a solid market position and potential for future expansion.
Read all positive factors

Europlasma SA (ALEUP) vs. iShares MSCI France ETF (EWQ)

Europlasma SA Business Overview & Revenue Model

Company Description
Europlasma S.A., established in 1992 and headquartered in Pessac, France, specializes with its subsidiaries in the engineering, construction, and deployment of plasma torch technology for diverse industrial uses across France. The company provides...
How the Company Makes Money
Europlasma generates revenue through the sale of its plasma technology systems and the operation of waste treatment facilities. Key revenue streams include the direct sale of plasma gasification units to businesses and municipalities, as well as l...

Europlasma SA Financial Statement Overview

Summary
Europlasma SA shows impressive revenue growth of 175.5% and a gross profit margin improvement to 53.3% in 2024. However, persistent profitability issues with a negative net profit margin of -36.0%, negative equity of -10.4 million, and negative cash flows of -12.4 million highlight significant financial strain and solvency risks.
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
25
Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue70.42M42.45M15.41M14.52M9.80M
Gross Profit30.20M-20.59M-17.41M-13.75M-9.59M
EBITDA-20.80M-3.36M-3.84M-5.30M-3.14M
Net Income-35.59M-15.29M-14.74M-15.92M-12.67M
Balance Sheet
Total Assets74.04M62.90M45.26M54.67M40.44M
Cash, Cash Equivalents and Short-Term Investments7.46M1.75M1.16M2.41M2.49M
Total Debt19.93M13.26M11.47M8.37M4.18M
Total Liabilities98.38M74.05M50.02M48.86M35.97M
Stockholders Equity-21.23M-10.41M-4.01M6.56M5.35M
Cash Flow
Free Cash Flow-20.35M-12.98M-12.17M-13.38M-23.75M
Operating Cash Flow-14.89M-11.47M-10.43M-10.48M-18.33M
Investing Cash Flow-420.00K-2.09M-953.00K-4.16M-5.70M
Financing Cash Flow21.00M14.14M10.14M14.56M22.25M

Europlasma SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
€1.43B10.4611.53%1.50%-2.88%24.77%
66
Neutral
€23.50B18.8917.55%4.73%-0.13%12.40%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
55
Neutral
€661.48M35.592.68%1.47%2.29%-59.18%
48
Neutral
€5.95M-2.48-116.61%4.64%22.28%
43
Neutral
€684.44K177.16%65.88%-162.85%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ALEUP
Europlasma SA
0.01
-1.74
-99.37%
FR:DBG
Derichebourg
8.69
3.55
69.27%
FR:SCHP
Seche Environnement
81.50
8.25
11.26%
FR:VIE
Veolia Environnement
31.74
3.90
14.00%
FR:ALESA
Ecoslops SA
1.14
0.28
32.56%
FR:GPE
Groupe Pizzorno Environnement SA
62.25
9.40
17.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025